The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left">ISS stage</td><td align="center">Definition</td><td align="center">Median OS</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">Stage I</td><td align="center">S<i>β</i><sub>2</sub>M less than 3.5 mg/L plus<br/>serum albumin ≥3.5 g/dL</td><td align="center">64 months</td></tr><tr><td align="left">Stage II</td><td align="center">Neither stage I nor stage III</td><td align="center">44 months</td></tr><tr><td align="left">Stage III</td><td align="center">S<i>β</i><sub>2</sub>M ≥5.5 mg/L</td><td align="center">29 months</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>ISS: International Staging System, OS: overall survival. <br/>S<i>β</i><sub>2</sub>M: serum beta 2 microglobulin.<br/></td></tr></table>

BioMed Research International

tab1

Table 1

Table 1: The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis 

Table 1 | The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis 